RBR-37f338招募中3 期
A randomized, double-blind, phase 3 study evaluating the efficacy and safety of ABP 980 compared with trastuzumab in subjects with HER2 positive early breast cancer
Associação Hospital de Caridade Ijuí0 个研究点开始时间: 2015年1月12日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 —（—）
- 性别
- Female
入选标准
- •Females equal or older than 18 years of age. Histologically confirmed invasive breast cancer. Planning for surgical resection of breast tumor and sentinel node (SN) or axillary lymph node resection. Planning neoadjuvant chemotherapy. HER2 positive disease defined as: 3+ overexpression by immunohistochemistry (IHC) or HER2 amplification by fluorescence in situ hybridization (FISH).
- •Measurable disease (assessment method used in order of priority: ultrasound, mammography, MRI, or physical examination) in the breast after diagnostic biopsy, defined as longest diameter equal to or longer than 2.0 cm. Known ER and PR hormone receptor status at study entry. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Left ventricular ejection fraction (LVEF) of equal to or more than 55% by 2D echocardiogram. Normal bone marrow function as defined by: absolute neutrophil count (ANC) higher than 1.5 x 10^9 g/dL (1,500/microL); platelets higher than 100 x 10^9 g/dL (100,000/microL); hemoglobin higher than 10.0 g/dL. Normal hepatic function as defined by: total bilirubin within normal institutional limits; aspartate aminotransferase (AST) and alanine aminotransferase (ALT); lower than 2.5 × the upper limit of normal (ULN); subjects with an elevated unconjugated bilirubin (Gilbert's syndrome) will be eligible if hepatic enzymes and function are otherwise within normal limits (ie, AST, ALT, and Alkaline Phosphatase are within normal limits), and there is no evidence of hemolysis. Normal renal function as defined by creatinine lower than 1.5 × ULN or estimated creatinine clearance (CrCl) equal to or higher than 50 mL/min calculated by the Cockcroft- Gault method.
- •Subjects must sign an IRB/EC-approved informed consent form before any study specific procedures.
排除标准
- •Bilateral breast cancer. Presence of known metastases. Received prior treatment, including chemotherapy, biologic therapy, radiation or surgery with the exception of diagnostic biopsy for primary breast cancer. Other concomitant active malignancy or history of malignancy in the past 5 years except treated basal cell carcinoma of the skin or carcinoma in situ of the cervix. Pre-existing clinically significant (equal to or higher than grade 2) peripheral neuropathy. Any history of documented or current congestive heart failure, current high-risk uncontrolled arrhythmias, current angina pectoris requiring a medicinal product, current clinically significant valvular disease, current evidence of transmural infarction on electrocardiogram (ECG), or current poorly controlled hypertension. Severe dyspnea at rest requiring supplementary oxygen therapy. History of positivity for hepatitis B surface antigen, hepatitis C virus, or HIV. Recent infection requiring a course of systemic anti-infectives that were completed equal to or less than 14 days before enrollment (with the exception of uncomplicated urinary tract infection). Woman of childbearing potential who is pregnant or is breast feeding. Woman of childbearing potential who is not consenting to use highly effective methods of birth control (eg, abstinence, sterilization, birth control pills, Depo-Provera injections, or contraceptive implants) during treatment and for an additional 4 months after the last administration of the protocol specified treatment. Currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study. Other investigational procedures while participating in this study are excluded. Subject has known sensitivity to any of the products to be administered during the study, including mammalian cell derived drug products, trastuzumab, murine proteins, or to any of the excipients. Subject previously has enrolled and/or has been randomized in this study. Subject likely to not be available to complete all protocol required study visits or procedures. History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the Investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
研究者
相似试验
进行中（未招募）
1 期
A study to test the efficacy and safety of riliprubart against the usual treatment of intravenous immunoglobulin (IVIg) in people with chronic inflammatory demyelinating polyneuropathy (CIDP)MedDRA version: 20.0Level: LLTClassification code: 10077384Term: Chronic inflammatory demyelinating polyneuropathy Class: 10029205Chronic Inflammatory Demyelinating PolyneuropathyCTIS2023-508338-33-00Sanofi-Aventis Recherche & Developpement229
已完成
3 期
A phase 3, randomized, double-blind study to evaluate the safety and efficacy of GS-9350-boosted Atazanavir versus Ritonavir-boosted Atazanavir each administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 infected, antiretroviral treatment-naive adults.NL-OMON38379Gilead Sciences8
已完成
3 期
A phase 3, randomized, double-blind study to evaluate the safety and efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 versus Ritonavir-Boosted Atazanavir plus Emitricitabine/Tenofovir Disoproxil Fumarate in HIV-1 infected, antiretroviral treatment-naive adults.Human Immunodeficiency Virus (HIV-1) Infections10047438NL-OMON39337Gilead Sciences8
进行中（未招募）
不适用
The trial is designed to determine the efficacy and safety of ABP 215 compared with Bevacizumab in subjects with advanced non-small cell lung cancerEUCTR2013-000738-36-DEAmgen Inc.620
进行中（未招募）
1 期
Double-Blind study comparing venetoclax and azacitidine versus placebo and azacitidine in patients that are newly diagnosed with Higher-Risk Myelodysplastic SyndromeMyelodysplastic SyndromeEUCTR2020-000744-55-GBAbbVie Deutschland GmbH & Co. KG500